Top-line results expected July 2025 as development of first-in-class OSA drug advancesNEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL ...

NEW YORK/MELBOURNE - Incannex Healthcare Inc. (NASDAQ:IXHL), a biotech company with a market capitalization of $20.6 million, announced Wednesday it has achieved database lock for its RePOSA Phase 2 ...

NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex” or the "Company”), a clinical-stage biopharmaceutical company advancing ...

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X Provided by GlobeNewswire Jun 18, 2025, 4:30:00 AM ...

When the database is released after FPFV, ongoing patient data collection doubles to at least 10 days. The impact of database-build delays is even greater by the time companies get to database lock.

DBA Corner DBA Corner focuses on issues of interest to data architects, database analysts and database administrators. Issues addressed by the column include data modeling and database design, ...

There are a few trends worth noting. As the first European states with a major presence in the New World, Portugal and Spain dominate the opening century of the trans-Atlantic slave trade, sending ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...